Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
- 6.5k Downloads
The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies.
Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda.
Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001.
High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine.
BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards.
KeywordsBone makers Bone turnover Fracture risk IOF Monitoring treatment Reference standards
This review was undertaken through grants from the International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine. It is endorsed by the Committee of Scientific Advisors of the IOF and the Education and Management Division of IFCC. None of the authors were compensated for their contribution.
Conflicts of interest
JAK, CC, OB, AJF, MMcC and MS have no competing interests with regard to markers of bone turnover. AG, SDV, TT and DAW declare no competing interests. HAM has participated in speakers bureaux for Roche Diagnostics Australia and Abbott Diagnostics with the provision of travel expenses. RE has received research funding and/or consultancy funding from Inverness Medical, Unipath, Roche Diagnostics and IDS.
- 8.Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRefGoogle Scholar
- 9.Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V (2009) Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19–26PubMedCrossRefGoogle Scholar
- 10.Vesper H, Cosman F, Endres DB, Garnero P, Hoyle NR, Kleerekoper M, Mallinak NJ (2004) Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases—approved guidelines. NCCLS document C48-A. ISBN 1-56238-539-9Google Scholar
- 16.Eisman J, Ebeling P, Ewald D, Flicker L, Holborow B, Nash P, Sambrook P, Seibel M, Stenmark J, Winzenberg T, Herjandono J (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners. www.racgp.org.au. Accessed March 2010
- 17.Sociedad Iberoamericana de Osteología y Metabolismo Mineral (SIBOMM) (2009) Ibero-American consensus on osteoporosis (Osteoporosis: Prevención, Diagnóstico y Tratamiento). www.aaomm.org.ar. Accessed March 2010
- 18.Lorenc R, Głuszko P, Karczmarewicz E, Księżopolska-Orłowska K, Misiorowski W, Franek E, Horst-Sikorska W, Kaleta M, Męczekalski B et al (2007) Recommendations on the diagnosis and treatment of osteoporosis. Reducing the incidence of fractures through effective prevention and treatment. Terapia 9:11–39Google Scholar
- 19.Singapore Ministry of Health (2008) Clinical practice guidelines for osteoporosis. Ministry of Health, Singapore. www.moh.gov.sg/cpg. Accessed March 2010
- 20.National Osteoporosis Guideline Group (2008) Osteoporosis—clinical guideline for prevention and treatment—executive summary. www.shef.ac.uk/NOGG. Accessed March 2010
- 21.Dawson-Hughes B, Lindsay R, Khosla S, Melton LJ, Tosteson AN, Favus MJ, Baim S (2008) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. www.nof.org. Accessed March 2010
- 22.Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring. Evidence report/technology assessment no. 28. Agency for Healthcare Research and Quality, RockvilleGoogle Scholar
- 31.Chesnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CCJ, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ (1997) Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29–37PubMedCrossRefGoogle Scholar
- 45.Viguet-Carin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML (2006) Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39:1073–1079CrossRefGoogle Scholar
- 46.Bauer DC (2001) Biochemical markers of bone turnover: the Study of Osteoporotic Fracture. In: Eastell R, Baumann M, Hoyle N, Wieczorek L (eds) Bone markers—biochemical and clinical perspectives. Martin Dunitz, London, pp 219–223Google Scholar
- 47.Dobnig H, Piswanger-Solkner JC, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Riedmuller G, Brueck C, Fahrleitner-Pammer A (2007) Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 92:1678–1686PubMedCrossRefGoogle Scholar
- 49.Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gärdsell P, Obrant KJ (1995) Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 10:1823–1829PubMedCrossRefGoogle Scholar
- 60.Greenfield DM, Hannon RA, Eastell R (2001) The association between bone turnover and fracture risk (Sheffield Osteoporosis study). In: Eastell R, Baumann M, Hoyle N, Wieczorek L (eds) Bone markers—biochemical and clinical perspectives. Martin Dunitz, London, pp 225–236Google Scholar
- 68.Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404–1410PubMedCrossRefGoogle Scholar
- 70.Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14:1583–1595PubMedCrossRefGoogle Scholar
- 72.Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical report, Sheffield, UK. WHO Collaborating Center, University of Sheffield. Available at http://www.shef.ac.uk/FRAX/index.htm. Accessed July 2009
- 74.Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, for the National Osteoporosis Guideline Group (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRefGoogle Scholar
- 76.Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas PD, Eisman J, Johnell O, on behalf of the International Osteoporosis Foundation and the National Osteoporosis Foundation, USA et al (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536PubMedCrossRefGoogle Scholar
- 79.Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253PubMedCrossRefGoogle Scholar
- 81.Vasikaran SD, Khan S, McCloskey EV, Kanis JA (1995) Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone Miner 17:517–520Google Scholar
- 83.Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276PubMedCrossRefGoogle Scholar
- 85.Bruyère O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, Detilleux J, Reginster J-Y (2010) Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21:1031–1036PubMedCrossRefGoogle Scholar
- 87.Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedCrossRefGoogle Scholar
- 90.Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut Iii CH, Brown J, Eriksen EF et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
- 91.Rosen C, Hochberg M, Bonnick S, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke R, Thompson D, de Papp A (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151PubMedCrossRefGoogle Scholar
- 93.Emkey R, Delmas P, Bolognese M, Borges J, Cosman F, Ragi-Eis S, Recknor C, Zerbini C, Neate C, Sedarati F, Epstein S (2009) Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 31:751–761PubMedCrossRefGoogle Scholar
- 94.Delmas PD, Recker RR, Chesnut CH, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798PubMedCrossRefGoogle Scholar
- 95.Delmas P, Adami S, Strugala C, Stakkestad J, Reginster J, Felsenberg D, Christiansen C, Civitelli R, Drezner M et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838–1846PubMedCrossRefGoogle Scholar
- 101.Glover S, Eastell R, McCloskey E, Rogers A, Garnero P, Lowery J, Belleli R, Wright T, John M (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone Miner 45:1053–1058Google Scholar
- 102.Greenspan S, Bone H, Ettinger M, Hanley D, Lindsay R, Zanchetta J, Blosch C, Mathisen A, Morris S, Marriott T (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339PubMedGoogle Scholar
- 108.Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389–397PubMedCrossRefGoogle Scholar
- 112.Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem Lab Med 47:694–702Google Scholar
- 117.Greenspan S, Resnick N, Parker R (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRefGoogle Scholar
- 120.Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255–261PubMedCrossRefGoogle Scholar
- 127.Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, The HORIZON-PFT Research Group (2009) Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544–1551PubMedCrossRefGoogle Scholar
- 129.Li Z, Meredith MP, Hoseyni MS (2002) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:7531–7588Google Scholar
- 138.Delmas P, Licata A, Reginster J, Crans G, Chen P, Misurski D, Wagman R, Mitlak B (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone Miner 39:237–243Google Scholar
- 144.Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRefGoogle Scholar
- 148.Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John GW, Kobold U, on behalf of the IFCC Working Group on HbA1c Standardization et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174PubMedCrossRefGoogle Scholar
- 152.Thienpont LM, van Uytfanghe K, Beastall G, Faix JD, Ieiri T, Miller WG, Nelson JC, Ronin C, Ross HA, Thijssen JH, Toussaint B, for the IFCC Working Group on Standardization of Thyroid Function Tests (2010) Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clin Chem 56:902–911PubMedCrossRefGoogle Scholar
- 156.Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Panteghini M, Welch MJ, Wu AHB, Kahn SE, for the American Association for Clinical Chemistry Cardiac Troponin I Standardization Committee (2006) Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem 52:1685–1692PubMedCrossRefGoogle Scholar